N🟁N

Molecular Insight Pharmaceuticals, Inc. to Present at 2008 RBC Capital Markets Healthcare Conference

  //health-fitness.news-articles.net/content/2008/ .. 8-rbc-capital-markets-healthcare-conference.html
  Published in Health and Fitness on Monday, December 8th 2008 at 7:45 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced todaythat John W. Babich, Ph.D., Interim Chairman and Chief Executive Officer of Molecular Insight Pharmaceuticals, Inc., will participate on a panel called "Tackling Tumors" at the2008 RBC Capital Markets Healthcare Conference on Wednesday, December 10, 2008. During the panel presentation and discussion, Dr. Babich will provide an overview of the company and its pipeline of molecular imaging radiopharmaceutical and targeted radiotherapeutic candidates for cancer. The panel presentation will take place at 1:30 p.m. Eastern Time at The Westin Times Square Hotel in New York, New York.

The panel presentation will be webcast live at [ http://www.wsw.com/webcast/rbc95/panel10/ ] and will be archived for 30 days. The webcast will also be available in the Investor Relations section of the Molecular Insight Pharmaceuticals website at [ www.molecularinsight.com ].

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The Company is focused on discovering, developing and commercializing innovative molecular imaging radiopharmaceuticals and targeted molecular radiotherapeutics with initial applications in the areas of cardiology and oncology. Molecular Insight's lead molecular imaging radiopharmaceutical product candidate, Zemiva™, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. The Company's imaging candidate, Trofex™, is in development for the detection of metastatic prostate cancer. Molecular Insight's lead molecular radiotherapeutic product candidates, Azedra and Onalta™, are being developed for detection and treatment of cancer. In addition, the Company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: [ www.molecularinsight.com ].

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Azedra^TM, Onalta^TM, Zemiva^TM, Trofex™ and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission (SEC). The Company's SEC filings are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at [ www.sec.gov ]. Press releases for Molecular Insight Pharmaceuticals, Inc. are available on our website: [ www.molecularinsight.com ]. If you would like to receive press releases via email, please contact: [ investor@molecularinsight.com ]. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.